Grafa News and Videos — Page 1150

Unity (NYSE:U), the prominent provider of tools for creating and growing real-time 3D content, and Meta (NASDAQ:META) announced an extended multi-year platform support and enterprise agreement on April 8, 2026.

Atkore (NYSE:ATKR) announced on April 8, 2026, the sale of its High-Density Polyethylene (HDPE) pipe and conduit business to Infra Pipes, a prominent North American manufacturer of polyethylene pipeline solutions.

Adagio Medical Holdings (NASDAQ:ADGM) announced on April 8, 2026, that the U.S. Food and Drug Administration (FDA) granted Investigational Device Exemption (IDE) approval to expand its FULCRUM-VT clinical trial.

Waters Corporation (NYSE:WAT) reached a significant regulatory milestone on April 8, 2026, with the U.S. Food and Drug Administration granting clearance for the Onclarity HPV Self-Collection Kit and approval for the associated assay for at-home use.

Odyssey Marine Exploration (NASDAQ:OMEX) and American Ocean Minerals announced on April 8, 2026, that they have entered into a definitive merger agreement to combine their businesses, creating a premier platform for deep-sea critical minerals research and resource extraction.

Barrick Gold (NYSE:B) welcomed a decisive legal victory on April 8, 2026, as the Ontario Court of Appeal dismissed an appeal brought by a group of Tanzanian residents concerning alleged human rights incidents near the North Mara gold mine.

iBio (NASDAQ:IBIO), an AI-driven pioneer in antibody discovery and development, announced on April 8, 2026, that it has received the necessary regulatory clearances to begin its Phase 1 clinical trial of IBIO-600, a novel candidate for the treatment of obesity.

Plus Therapeutics (NASDAQ:PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics for central nervous system (CNS) cancers, announced on April 8, 2026, that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to REYOBIQ™ (rhenium Re186 obisbemeda).

Osisko Gold Royalties(NYSE:OR) reported record-breaking preliminary financial results for the first quarter of 2026 on April 8, bolstered by strong production across its core royalty portfolio and high precious metal prices.

Bausch + Lomb (NYSE:BLCO), a leader in eye health, announced on April 8, 2026, that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Bi-Blade+ dual-port vitrectomy cutter and an advanced Adaptive Fluidics update for the Stellaris Elite® Vision Enhancement System.